	US 12,343,372 B2
	Desmopressin oral compositions
Yu-Hsing Tu, West Windsor, NJ (US); Kalyan Kathala, Monroe, NJ (US); Romona Bhattacharya, Franklin Park, NJ (US); Yingjun Fan, Plainsboro, NJ (US); and Ashok Perumal, Monmouth Junction, NJ (US)
Assigned to Tulex Pharmaceuticals Inc., Cranbury, NJ (US)
Filed by Tulex Pharmaceuticals Inc., Cranbury, NJ (US)
Filed on Nov. 21, 2024, as Appl. No. 18/955,504.
Application 18/955,504 is a division of application No. 18/625,923, filed on Apr. 3, 2024, granted, now 12,214,010.
Claims priority of provisional application 63/457,005, filed on Apr. 4, 2023.
Prior Publication US 2025/0090623 A1, Mar. 20, 2025
Int. Cl. A61K 38/095 (2019.01); A61K 9/00 (2006.01); A61K 47/10 (2017.01); A61K 47/12 (2006.01); A61K 47/14 (2017.01); A61K 47/18 (2017.01); C07K 7/16 (2006.01)

CPC A61K 38/095 (2019.01) [A61K 9/0053 (2013.01); A61K 47/10 (2013.01); A61K 47/12 (2013.01); A61K 47/14 (2013.01); A61K 47/183 (2013.01); C07K 7/16 (2013.01)]

29 Claims

1. A method of treating a disease or condition, or symptoms thereof, comprising administering a therapeutically effective amount of a liquid pharmaceutical composition to a subject in need thereof, the liquid pharmaceutical composition comprising:

a) desmopressin acetate;

b) a two-component, dual-functional, preservative-buffer system that comprises sodium benzoate and benzoic acid; and

c) water;

wherein the disease or condition, or symptoms thereof is selected from the group consisting of: diabetes insipidus, nocturnal enuresis, nocturia, hypothalamic injury-induced obesity (HIO), hemophilia A, von willebrand disease, postoperative bleeding, polyurea, and high blood urea levels.